Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis AG vs. Bausch & Lomb

This article was originally published in The Gray Sheet

Executive Summary

Ciba Vision parent files patent infringement suit in Dublin alleging B&L PureVision extended-wear contact lenses infringe Irish Patent 819258 for Ciba's Focus Night & Day lenses. The firm is seeking an injunction on all manufacturing and sales. B&L world manufacturing headquarters for PureVision are located in Waterford, Ireland; the firm moved the plant from its Rochester, N.Y. site last year. B&L may not make or sell the lenses in the U.S. until April 2005, following a verdict on a separate patent case (1"The Gray Sheet" Feb. 17, 2003, p. 11). If Ciba prevails in Ireland, PureVision would be banned from the country until 2016. A similar suit involving the "Nicolson" patent is ongoing in federal district court in Gainesville, Ga.; a trial date will be set this year. The Nicolson patent expires in 2014...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018054

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel